We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

181 hedge funds and large institutions have $2.1B invested in GW Pharmaceuticals Plc American Depositary Shares in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 47 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 17

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

17% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 47

10% more capital invested

Capital invested by funds: $1.91B → $2.1B (+$198M)

6% more funds holding

Funds holding: 170181 (+11)

35% less call options, than puts

Call options by funds: $50.3M | Put options by funds: $77M

Holders
181
Holders Change
+11
Holders Change %
+6.47%
% of All Funds
4.51%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.12%
New
31
Increased
55
Reduced
47
Closed
17
Calls
$50.3M
Puts
$77M
Net Calls
-$26.7M
Net Calls Change
-$5.5M
Name Holding Trade Value Shares
Change
Change in
Stake
BA
151
Bristlecone Advisors
Washington
$9K +$9.21K +86 New
BDWM
152
Brewin Dolphin Wealth Management
Ireland
$8.42K +$8.89K +83 New
MWM
153
MinichMacGregor Wealth Management
New York
$8K +$4.28K +40 +100%
MSFP
154
Mark Sheptoff Financial Planning
Connecticut
$7K
Toronto Dominion Bank
155
Toronto Dominion Bank
Ontario, Canada
$7K +$7.18K +67 New
FDCDDQ
156
Federation des caisses Desjardins du Quebec
Quebec, Canada
$6.6K
GEA
157
Glen Eagle Advisors
New Jersey
$6.09K -$6.43K -60 -50%
LWCFA
158
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$6K
ST
159
Smithfield Trust
Pennsylvania
$6K
TJHA
160
Thomas J. Herzfeld Advisors
Florida
$6K
SEI Investments
161
SEI Investments
Pennsylvania
$5K -$10.7K -100 -66%
AIM
162
Advantage Investment Management
Iowa
$5K
SIAP
163
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$4K
CFA
164
Carroll Financial Associates
North Carolina
$4K +$3.75K +35 New
Fifth Third Bancorp
165
Fifth Third Bancorp
Ohio
$3K
HDIM
166
Hanson & Doremus Investment Management
Vermont
$3K
Bessemer Group
167
Bessemer Group
New Jersey
$2K
FBT
168
First Bank & Trust
South Dakota
$2K
RFA
169
Reilly Financial Advisors
California
$2K
TIM
170
Tortoise Investment Management
New York
$2K
WAS
171
Winch Advisory Services
Wisconsin
$2K
Thrivent Financial for Lutherans
172
Thrivent Financial for Lutherans
Minnesota
$2K +$1.82K +17 New
KIG
173
Kessler Investment Group
Indiana
$2K +$2.04K +19 New
WEC
174
Winslow Evans & Crocker
Massachusetts
$1.02K -$8.03K -75 -88%
GRP
175
Global Retirement Partners
California
$1K

GWPH Hedge Fund Activity: Q3 2017 in Review

181 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q3 2017, worth a combined $2.1B — up 10% from $1.91B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new GWPH positions and 17 closed out — a net gain of 14 holders — while 55 added to existing stakes and 47 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $64.5M. The largest seller was Fidelity Investments, cutting an estimated $26.1M.

  • 181 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q3 2017, up from 170 in Q2 2017.
  • Funds reported $2.1B of GW Pharmaceuticals Plc American Depositary Shares stock for Q3 2017, up 10% quarter-over-quarter.
  • 31 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q3 2017 and 17 closed out, a net change of +14 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q3 2017 was Consonance Capital Management, an estimated $64.5M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q3 2017 was Fidelity Investments, an estimated $26.1M sold.

Based on aggregated 13F filings for Q3 2017.